BACTROBAN MUPIROCINMUPIROCIN

bactroban ointment

Bactroban Ointment Official FDA information, side effects and uses. A B C D E F G H I J K L M N O P Q R S T U V W X Y Z C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption ( 1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.The efficacy of topical Bactroban Ointment in impetigo was tested in 2 studies. In the first, patients with impetigo were randomized to receive either Bactroban Ointment or vehicle placebo 3 times daily for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations (adults and pediatric patients included) were 71% for BACTROBAN OINTMENT (n = 49) and 35% for vehicle placebo (n = 51). Pathogen eradication rates in the evaluable populations were 94% for BACTROBAN OINTMENT and 62% for vehicle placebo. There were no side effects reported in the group receiving Bactroban Ointment.